Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical Implications
Cytochrome P450 (CYP450) enzymes are pivotal in the metabolism of numerous anticancer agents, with CYP3A4 being the predominant isoform involved. Inhibition of CYP450 enzymes is a major mechanism underlying clinically significant drug-drug interactions (DDIs), particularly in oncology, where polypha...
Saved in:
Main Authors: | Martin Kondža, Josipa Bukić, Ivan Ćavar, Biljana Tubić |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-05-01
|
Series: | Drugs and Drug Candidates |
Subjects: | |
Online Access: | https://www.mdpi.com/2813-2998/4/2/24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Computational drug–drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel
by: Priyadharshini Ananthathandavan, et al.
Published: (2024-12-01) -
PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis
by: Ray Manneh, et al.
Published: (2025-07-01) -
Pharmacokinetic interaction of drugs, the metabolisable cytochrome P450 isoenzyme CYP2C9
by: O. G. Gribakina, et al.
Published: (2020-04-01) -
A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01) -
Isoform CYP1A2, as a part of the cytochrome P450 superfamily
by: Y. G. Novickaya, et al.
Published: (2014-04-01)